A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the ovarian response after controlled ovarian stimulation with mixed protocols of follitropin delta (REKOVELLE) and highly purified human menopausal gonadotropin (MENOPUR) in women undergoing an assisted reproductive technology programme

Status

Not yet recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500308-23-00

Enrollment

115

Registered

2022-11-08

Start date

Unknown

Completion date

Unknown

Last updated

2022-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle

Brief summary

Number of fertilised (2 pronuclei [2PN]) oocytes at 19±2 hours after insemination

Interventions

DRUGFyremadel

DRUG0

DRUG25 mg/0

DRUG5 ml oplossing voor injectie in voorgevulde spuit

DRUGDecapeptyl 0

DRUG1 mg/1 ml

DRUGoplossing voor injectie

DRUGMenopur

DRUGOvitrelle 250 micrograms/0.5 mL solution for injection in pre-filled syringe

DRUGREKOVELLE 72 micrograms/2.16 mL solution for injection in a pre-filled pen

DRUGOvitrelle 250 micrograms solution for injection in pre-filled pen

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Number of fertilised (2 pronuclei [2PN]) oocytes at 19±2 hours after insemination	—

Countries

Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026